Genodix Products for Immune Disorders

Genodix has made great advances in the treatment of rheumatoid arthritis. Unalis represents a "first in class" drug which uses a novel binding site to disrupt the immune system's attack on the body's cartilage. The potency of Unalis requires only a single dose per day, making compliance among the growing elderly population much higher.






After years of research and a breakthrough in the delivery of small molecules into the cell nucleus, Genodix has developed a revolutionary new drug for the treatment of systemic lupus. Taken twice a day, Ficonazole has been shown to reduce the progress of lupus, nearly doubling the life expectancy of patients and reducing the levels of steroid treatments.






Effective treatment of multiple sclerosis has long been a goal of Genodix researchers. Years of hard work on methods of breaking up sclerotic plaques lead to the serindipidous discovery of a small molecule which bound to a set of proteins on Schwann cells--least two of these proteins are also those which are bound in the auto-immune response of multiple sclerosis. The presence of this small molecule discovered by Genodix researchers (marketed as Naramed) provides a strong level of protection for the Schwann cells. In clinical studies, treatment with Naramed was able to virtually halt the progress of multiple sclerosis in both the peripheral and central nevous system.






Nardolone is a steriodal treatment for the rheumatic fever and glomerulo nephritis which can result from infections by beta-hemolytic streptococcus. Steroid treatments typically have a wide range of side effects, however clinical trials have shown Nardolone to have lowest incidence of serious side effects.